Replies to post #638787 on MOMO'S BREAKOUT BOARD

[Aragorn1]

VPRS - read this and u will buy with both hands - dollars entirely possible here:

8K Release Today, change in officers 4/26/11

Possible R/M with Chinese Biotech Pharmacy company it seems. New CEO of VPRS is same CEO as Shanghai MediPharm Biotech.

This shows some of there products and revenue projections.
http://www.wallstreetresearch.org/reports/profile_medipharm.pdf

Quote:
Following 15 years of R&D in antibody related biopharmaceuticals, the company has a strong intellectual prop-erty portfolio, including Vivatuxin®, a chimeric tumor necrosis therapy approved by China’s State Food and Drug Administra-tion for lung cancer and launched in 2007



Quote:
MediPharm plans to invest in Radiation-Protective Fa-cilities (RPFs) in 150 China Tier 3 hospitals, with each hospital requiring investment of $75,000 for a total of $11.3 million. Vivatuxin® is expected to generate $45.1 million revenue and $13.8 million net profit in 2011, $92.8 million revenue and $36.1 million net profit in 2012, and $143.3 million revenue and $52.1 million net profit in 2013.



Quote:
Through a strategic marketing collaboration study with the Ministry of Health of China currently covering 101 hospitals, the company has agreements to supply 20,000 doses of Vivatuxin®, priced at $3,000 each, used for the treatment of advanced lung cancer patients